argenx SE (ARGX)
388.20
-5.22
(-1.33%)
USD |
NASDAQ |
May 03, 16:00
388.62
+0.42
(+0.11%)
After-Hours: 20:00
argenx Total Return Price: 388.20 for May 3, 2024
Total Return Price Chart
Historical Total Return Price Data
Date | Value |
---|---|
May 03, 2024 | 388.20 |
May 02, 2024 | 393.42 |
May 01, 2024 | 383.34 |
April 30, 2024 | 375.50 |
April 29, 2024 | 375.29 |
April 26, 2024 | 372.80 |
April 25, 2024 | 368.60 |
April 24, 2024 | 375.00 |
April 23, 2024 | 375.08 |
April 22, 2024 | 368.75 |
April 19, 2024 | 360.23 |
April 18, 2024 | 358.41 |
April 17, 2024 | 366.20 |
April 16, 2024 | 370.68 |
April 15, 2024 | 376.26 |
April 12, 2024 | 378.02 |
April 11, 2024 | 379.65 |
April 10, 2024 | 382.78 |
April 09, 2024 | 384.14 |
April 08, 2024 | 386.71 |
April 05, 2024 | 387.03 |
April 04, 2024 | 386.88 |
April 03, 2024 | 398.49 |
April 02, 2024 | 397.11 |
April 01, 2024 | 397.33 |
Date | Value |
---|---|
March 28, 2024 | 393.72 |
March 27, 2024 | 398.59 |
March 26, 2024 | 397.57 |
March 25, 2024 | 398.42 |
March 22, 2024 | 402.68 |
March 21, 2024 | 396.88 |
March 20, 2024 | 356.95 |
March 19, 2024 | 359.37 |
March 18, 2024 | 361.54 |
March 15, 2024 | 371.28 |
March 14, 2024 | 378.64 |
March 13, 2024 | 381.76 |
March 12, 2024 | 387.94 |
March 11, 2024 | 385.00 |
March 08, 2024 | 387.80 |
March 07, 2024 | 388.68 |
March 06, 2024 | 390.66 |
March 05, 2024 | 388.69 |
March 04, 2024 | 390.32 |
March 01, 2024 | 393.49 |
February 29, 2024 | 380.01 |
February 28, 2024 | 397.70 |
February 27, 2024 | 411.20 |
February 26, 2024 | 410.35 |
February 23, 2024 | 409.52 |
Total Return Price Definition
The total return price allows investors to view the performance of a security inclusive of both price appreciation and dividends/distributions.
Total Return Price Range, Past 5 Years
106.59
Minimum
Oct 08 2019
548.43
Maximum
Jul 21 2023
300.55
Average
309.30
Median
May 31 2022
Total Return Price Benchmarks
TC BioPharm (Holdings) PLC | 1.46 |
Trinity Biotech PLC | 1.802 |
Ascendis Pharma A/S | 137.20 |
Adaptimmune Therapeutics PLC | 1.19 |
Biodexa Pharmaceuticals Plc | 1.18 |